将纯化的在大肠杆菌中表达的鹦鹉热衣原体(Cps)的重组主要外膜蛋白(MOMP)与油佐剂混合。
The purified recombinant major outer-membrane protein (MOMP) of Chlamydia psittaci (Cps) expressed in E. coli was mixed with oil adjuvant.
那么这个佐剂又是怎样起作用的呢?
生产商决定一种制品配方是否使用佐剂。
Manufacturers decide whether a product is formulated with or without an adjuvant.
佐剂的安全性是一个十分重要、但又被忽视了的问题。
世卫组织可以推动佐剂安全性研究,并进一步制订相应指南。
WHO might promote research and further develop guidelines on adjuvant safety.
无论如何,在考虑佐剂安全性问题的早期阶段不可能不使用动物。
Nevertheless, animals cannot be dispensed with in the early consideration of a safety profile.
如条件适宜(如,使用新型佐剂),应利用动物模型开展生殖毒性研究。
Where appropriate (e.g. with use of novel adjuvants), reproductive toxicity studies using animal models should be conducted.
在过去的10年间,有大量的新型佐剂已被开发出来并已进行临床评价。
During the past decade, a large number of novel adjuvants have been developed and evaluated clinically.
角鲨烯本身并不是一种佐剂,但添加表面活性剂的角鲨烯乳剂可增强免疫应答。
Squalene by itself is not an adjuvant, but emulsions of squalene with surfactants do enhance the immune response.
在讨论安全问题时,需要对佐剂对免疫应答的影响及其作用机制有透彻的了解。
Safety issues will require a thorough understanding of the effects of adjuvants on the immune response and related mechanisms.
Fauci博士说在孕妇的研究在9月开始,研究将使用一种佐剂以强化免疫系统。
Dr Fauci said studies in pregnant women should begin in September, as will studies using an immune system booster called an adjuvant.
短期和长期安全性评价和预测非常重要,同样重要的还有佐剂本身的药物代谢动力学评价。
Short-term and long-term safety evaluation and prediction are important, as is the evaluation of the pharmacokinetics of the adjuvant alone.
所有这些都需要一个在临床、科研和管理方面的新方法,来关注佐剂的短期和长期安全性问题。
All this requires a new clinical, scientific and regulatory approach, with attention to the short - and long-term safety of adjuvants.
角鲨烯本身并不是一种佐剂,但添加表面活性剂后的角鲨烯乳剂加入至抗原后可增强免疫应答。
Squalene alone is not an adjuvant, but emulsions of squalene with surfactants enhance the immune response when added to antigens.
WHO不久将推出一个针对佐剂临床评价的网站,内容包括佐剂的安全性及其临床试验的数据库。
A WHO web site on adjuvants in clinical evaluation including adjuvant safety, with a database of clinical trials, will be made available shortly.
佐剂引起的不良反应事件应予记录和审阅,相关信息应可供查阅,在这方面世卫组织也应发挥其作用。
Adverse events attributable to adjuvants need to be documented and reviewed, and the information made available. That is another important role for WHO.
有些大流行性流感疫苗含有佐剂以便减少病毒抗原的使用量(抗原是能够刺激免疫反应的一种物质)。
Some pandemic vaccines contain an adjuvant to reduce the amount of virus antigen to be used (an antigen is a substance capable of stimulating an immune response).
含佐剂的季节性流感疫苗以前主要是给老年人使用,因而我们目前还不清楚它在年轻人身上是否有副作用。
The seasonal flu vaccines with adjuvants have mostly been given to older people, so we cannot yet be sure that these vaccines do not have very rare side effects in younger people.
由于佐剂具有其自身的药理学特性,可能会影响疫苗的免疫原性和安全性,因此对其进行安全性评估是必不可少的。
Since adjuvants have their own pharmacological properties, which might affect both the immunogenicity and the safety of vaccines, safety assessment is essential.
Cohen博士指出早前疫苗失败而此次疫苗成功的原因之一是新型佐剂(指能够增加机体免疫反应的成分)的添加。
Dr Cohen points to novel adjuvants (ingredients that increase the body’s response to vaccines) as one of the reasons why the vaccine works when many earlier versions failed.
这主要是因为高效“佐剂(adjuvant)”的应用。此类物质可在减少昂贵抗原用量的同时大大增强抗原效力。
The key is the use of sophisticated “adjuvants”, delivery agents that can reduce the amount of precious antigen required even as they greatly enhance its effectiveness.
专家们注意到各种大流行性流感疫苗,包括减毒活疫苗以及加入佐剂和未加佐剂的灭活疫苗,现在已由管制当局颁发使用许可证。
The experts noted that a variety of pandemic vaccines, including live attenuated and both adjuvanted and non-adjuvanted inactivated vaccines, have now been licensed for use by regulatory authorities.
用于大流行性流感疫苗的佐剂已获许用于其它疫苗(例如乙型肝炎,季节性或大流行性流感疫苗,或其它疫苗),并具有安全的使用记录。
Adjuvants used with pandemic influenza vaccines are already licensed for use with other vaccines (e.g. hepatitis B, seasonal or pandemic influenza vaccines, or others), and have a safe track record.
尽管为了使疫苗更有效,有时会在疫苗中添加称为佐剂的物质,但是在美国出售的疫苗,包括2009h1n1疫苗,不含任何佐剂。
Although substances called adjuvants are sometimes added to vaccines to make them more effective, no flu vaccine sold in the United States, including the H1N1 2009 vaccine, contains any adjuvants.
关于佐剂安全性以及利用临床前期模型评估佐剂安全性的问题已按期在2005年12月4 - 8日举行的WHO佐剂研讨会上进行讨论。
Adjuvant safety and the use of preclinical models to assess adjuvant safety were due to be discussed at the WHO conference on adjuvants on 4-8 December 2005.
MF 59就是一种含角鲨烯的佐剂,最先于1997年被意大利主管部门批准添加至一种季节性亚单位流感疫苗,其后又被其他几个国家批准上市。
MF59, a proprietary adjuvant containing squalene, is included in a seasonal subunit influenza vaccine licensed by the Italian regulatory authority in 1997 and subsequently by several other countries.
MF 59就是一种含角鲨烯的佐剂,最先于1997年被意大利主管部门批准添加至一种季节性亚单位流感疫苗,其后又被其他几个国家批准上市。
MF59, a proprietary adjuvant containing squalene, is included in a seasonal subunit influenza vaccine licensed by the Italian regulatory authority in 1997 and subsequently by several other countries.
应用推荐